Medication leaflets

Active substance

Results for the substance eftrenonacog alfa

5 results

About this active substance

Eftrenonacog alfa is a recombinant factor IX used for the treatment and prevention of bleeding episodes in patients with hemophilia B. This medication is indicated for both prophylactic use and the control of acute bleeding.

One advantage of eftrenonacog alfa is its long duration of action, allowing for less frequent administration compared to other hemophilia treatments. This can improve patients' quality of life by reducing the frequency of injections.

The medication is well-tolerated by most patients, but side effects such as headaches, nausea, or injection site reactions may occur. It is important for patients to be monitored for potential allergic reactions or the development of inhibitors.

Eftrenonacog alfa is a modern therapeutic option that provides effective control of hemophilia B, helping to prevent bleeding complications and maintain an active lifestyle.